Impact of [18F]FET-PET on MRI-Based Radiotherapy Target Volumes in Newly Diagnosed Glioblastoma:Results from the FET-PET in Glioblastoma (FIG) Study TROG 18.06.

IF 13.1 1区医学 Q1 CLINICAL NEUROLOGY

Neuro-oncology Pub Date : 2026-09-24 DOI:10.1093/neuonc/noag229

E-S Koh, R J Francis, G Ninatti, I Ruisi, M A Ebert, E Lau, A Whitehead, J Descallar, E H Barnes, S T Lee, E L Thomas, M B Pinkham, M Back, S P Ng, N Bucknell, H K Gan, O Cook, R Dykyj, A Moore, S Porter, Patricia Banyer, F E Scott, D L Bailey, N Barry, T Akhurst, R Alipour, A Bece, C Bettingdon, S Beuzeville, J H Chang, B Chua, C Clark, J Croker, S Gill, P Gorayski, E Hsiao, K Jung, S Khan, D Krishna, I Kirkwood, H Le, P Lin, T Ly, M McGuiness, S Ngai, D A Pattison, C Phillips, A P Pullar, G Schembri, J Sia, F Syed, P Thomas, W Vallat, M Wada, D Wong, J Yap, T C Yeow, A K Nowak, F Foroudi, M Rosenthal, P Roach, L Adda, R De Abreu Lourenco, B A Moffat, C Brighi, A Lasocki, L Holloway, M Fay, A M Scott

{"title":"Impact of [18F]FET-PET on MRI-Based Radiotherapy Target Volumes in Newly Diagnosed Glioblastoma:Results from the FET-PET in Glioblastoma (FIG) Study TROG 18.06.","authors":"E-S Koh, R J Francis, G Ninatti, I Ruisi, M A Ebert, E Lau, A Whitehead, J Descallar, E H Barnes, S T Lee, E L Thomas, M B Pinkham, M Back, S P Ng, N Bucknell, H K Gan, O Cook, R Dykyj, A Moore, S Porter, Patricia Banyer, F E Scott, D L Bailey, N Barry, T Akhurst, R Alipour, A Bece, C Bettingdon, S Beuzeville, J H Chang, B Chua, C Clark, J Croker, S Gill, P Gorayski, E Hsiao, K Jung, S Khan, D Krishna, I Kirkwood, H Le, P Lin, T Ly, M McGuiness, S Ngai, D A Pattison, C Phillips, A P Pullar, G Schembri, J Sia, F Syed, P Thomas, W Vallat, M Wada, D Wong, J Yap, T C Yeow, A K Nowak, F Foroudi, M Rosenthal, P Roach, L Adda, R De Abreu Lourenco, B A Moffat, C Brighi, A Lasocki, L Holloway, M Fay, A M Scott","doi":"10.1093/neuonc/noag229","DOIUrl":null,"url":null,"abstract":"Background: The FET-PET in Glioblastoma (FIG) study (TROG 18.06) assessed the impact of adding FET-PET to MRI on radiotherapy gross tumor volume delineation in newly diagnosed glioblastoma.Methods: This multicenter prospective phase 2 study evaluated participants with newly diagnosed glioblastoma IDH-wildtype undergoing post-operative MRI and FET-PET imaging before adjuvant radiotherapy, delivered according to standard MRI-based planning. The FET-PET-positive biological tumor volume (BTV) was used to derive the Hybrid (FET-PET+MRI) gross tumor volume (Hybrid-GTV). Primary outcomes were: 1) BTV excluded from the GTV defined on MRI alone (MR-GTV); 2) Hybrid-GTV excluded from the MR-GTV with both comparisons analyzed by non-overlap volume (cm3 and %), dosimetry (D98 and V95) and spatial similarity metrics; 3) clinically meaningful change in GTV non-overlap percentage volume with the addition of FET-PET.Results: There were 172 participants recruited, n = 140 evaluable. Median BTV was 23.1 cm3, median MR-GTV was 32.1 cm3, and median Hybrid-GTV was 46.0 cm3. Hybrid-GTV was significantly larger than the MR-GTV (p < 0.001), with a larger Hybrid-GTV observed in 83% of cases. Comparing BTV to MR-GTV, median non-overlap volume was 10.1 cm3 and non-overlap percentage volume 53.5%. Comparing Hybrid-GTV to MR-GTV, median non-overlap volume was 14.9 cm3 and non-overlap percentage volume 33.9%. D98 and V95 were lower for the Hybrid-GTV than for the MR-GTV, suggesting lower dose coverage. Applying a > 20% non-overlap percentage volume threshold, 76% of participants had a meaningful change in GTV with the addition of FET-PET.Conclusion: FET-PET differed significantly from MRI-based GTV delineation, with its incorporation leading to a clinically meaningful change in GTV in the majority of participants.","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":13.1000,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noag229","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The FET-PET in Glioblastoma (FIG) study (TROG 18.06) assessed the impact of adding FET-PET to MRI on radiotherapy gross tumor volume delineation in newly diagnosed glioblastoma.

Methods: This multicenter prospective phase 2 study evaluated participants with newly diagnosed glioblastoma IDH-wildtype undergoing post-operative MRI and FET-PET imaging before adjuvant radiotherapy, delivered according to standard MRI-based planning. The FET-PET-positive biological tumor volume (BTV) was used to derive the Hybrid (FET-PET+MRI) gross tumor volume (Hybrid-GTV). Primary outcomes were: 1) BTV excluded from the GTV defined on MRI alone (MR-GTV); 2) Hybrid-GTV excluded from the MR-GTV with both comparisons analyzed by non-overlap volume (cm3 and %), dosimetry (D98 and V95) and spatial similarity metrics; 3) clinically meaningful change in GTV non-overlap percentage volume with the addition of FET-PET.

Results: There were 172 participants recruited, n = 140 evaluable. Median BTV was 23.1 cm3, median MR-GTV was 32.1 cm3, and median Hybrid-GTV was 46.0 cm3. Hybrid-GTV was significantly larger than the MR-GTV (p < 0.001), with a larger Hybrid-GTV observed in 83% of cases. Comparing BTV to MR-GTV, median non-overlap volume was 10.1 cm3 and non-overlap percentage volume 53.5%. Comparing Hybrid-GTV to MR-GTV, median non-overlap volume was 14.9 cm3 and non-overlap percentage volume 33.9%. D98 and V95 were lower for the Hybrid-GTV than for the MR-GTV, suggesting lower dose coverage. Applying a > 20% non-overlap percentage volume threshold, 76% of participants had a meaningful change in GTV with the addition of FET-PET.

Conclusion: FET-PET differed significantly from MRI-based GTV delineation, with its incorporation leading to a clinically meaningful change in GTV in the majority of participants.

查看原文本刊更多论文

[18F]FET-PET对新诊断的胶质母细胞瘤mri放疗靶体积的影响：来自FET-PET在胶质母细胞瘤中的结果（FIG）研究TROG 18.06。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuro-oncology 医学-临床神经学

CiteScore

27.20

自引率

6.30%

发文量

1434

审稿时长

3-8 weeks

期刊介绍： Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field. The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.